1-15 of 15
Jeffrey P. Sharman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Analysis of Healthcare Provider Practice Patterns from Individual Patient Cases Entered into an Online Treatment Decision Tool for Chronic Lymphocytic Leukemia (CLL)

Kristen M Rosenthal, PhD, Farrukh T. Awan, MD MS, Steven Coutre, MD, Jeffrey A. Jones, MD MPH, MBA, Jeffrey P. Sharman, MD, Kevin L Obholz, PhD, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5614.
https://doi.org/10.1182/blood.V130.Suppl_1.5614.5614
Published: 2017
Journal Articles

Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

Jeffrey P. Sharman, MD, Habte Yimer, MD, Michael Boxer, MD, Nicholas Di Bella, Sunil Babu, Jia Li, PhD, Yong Mun, Peter Trask, Anthony Masaquel, MPH, PhD, Carolina M Reyes, PhD, Alexey Danilov, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 683.
https://doi.org/10.1182/blood.V130.Suppl_1.683.683
Published: 2017
Journal Articles

Evaluating the Efficacy, Safety, and Dose Dependent Activities of Entospletinib in Patients with Chronic Lymphocytic Leukemia

Jeffrey P. Sharman, MD, Kathryn S. Kolibaba, MD, Jose Azar, MD, Rama Balaraman, MD, Roger M. Lyons, MD, Mitchell R. Smith, MD PhD, Esteban Abella-Dominicis, MD, Wei Ye, PhD, Wen Shi, MD PhD, Thomas Giever, DO, Andres Forero-Torres, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 832.
https://doi.org/10.1182/blood.V130.Suppl_1.832.832
Published: 2017
Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis

Anas Younes, MD, Burke M. John, Catherine S Diefenbach, Silvia Ferrari, Cyrus Kahn, Jeffrey P. Sharman, MD, Monica Tani, Chaitra S. Ujjani, MD, Umberto Vitolo, MD, Sam Yuen, Paul Woodard, Kirsten Mundt, Günter Fingerle-Rowson, Surya Chitra, Gila Sellam, Rodica Morariu-Zamfir, Michael Gilbertson
Journal: Blood
Blood (2017) 130 (Supplement 1): 481.
https://doi.org/10.1182/blood.V130.Suppl_1.481.481
Published: 2017
Journal Articles

MCL Treatment Patterns and Outcomes: A Community Oncology Practice Experience

Jeffrey P. Sharman, MD, Jenny L Black-Shinn, MPH, PhD, Jamyia Clark, MPH, Sudeep Karve, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4684.
https://doi.org/10.1182/blood.V130.Suppl_1.4684.4684
Published: 2017
Journal Articles

Understanding Ibrutinib Treatment Discontinuation Patterns for Chronic Lymphocytic Leukemia

Jeffrey P. Sharman, MD, Jenny L Black-Shinn, MPH, PhD, Jamyia Clark, MPH, Bojena Bitman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4060.
https://doi.org/10.1182/blood.V130.Suppl_1.4060.4060
Published: 2017
Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Andres Forero-Torres, MD, Kathryn S. Kolibaba, MD, Herve Tilly, Gilles Salles, MD PhD, Lijia Wang, Calvin Lee, Jeffrey P. Sharman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4120.
https://doi.org/10.1182/blood.V130.Suppl_1.4120.4120
Published: 2017
Journal Articles

Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma after Prior Rituximab

Kathryn S. Kolibaba, MD, Mikhail Shtivelband, MD PhD, Edwin C. Kingsley, MD, Mehdi M. Moezi, MD, Donald Richards, MD PhD, Jeffrey P. Sharman, MD, Feng Xiaoshu, MS, Megan Cannan, B.S, Rafik Fellague-Chebra, MD, Roger M. Lyons, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1500.
https://doi.org/10.1182/blood.V130.Suppl_1.1500.1500
Published: 2017
Journal Articles

A Phase I Study of the Anti-CD79b THIOMAB TM -Drug Conjugate DCDS0780A in Patients (pts) with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Alex F. Herrera, MD, Manish R Patel, MD, John M. Burke, MD, Ranjana H. Advani, MD, Bruce D. Cheson, MD, Jeffrey P. Sharman, MD, Elicia Penuel, Andrew G. Polson, PhD, Ning Leng, PhD, Chunze Li, PhD, Eva Schuth, PhD, Anjali Vaze, PhD, Divya Samineni, PhD, Rebecca Elstrom, MDMA, Catherine S Diefenbach
Journal: Blood
Blood (2017) 130 (Supplement 1): 4129.
https://doi.org/10.1182/blood.V130.Suppl_1.4129.4129
Published: 2017
Journal Articles

A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Julie Huang, PhD, Ming Lin, PhD, John C. Byrd, MD, Asher A. Chanan-Khan, MD, Richard R. Furman, MD, Michael Hallek, MD, Peter Hillmen, MBChB, PhD, Jeffrey Jones, MD, Jeffrey P. Sharman, MD, Lucille Ferrante, MD, Vijay Reddy, MD PhD, Lyndah K. Dreiling, MD, Henry Adewoye, MD, Ronald Dubowy, MD, Angela Howes, PhD, Danelle F. James, MD MAS, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4303.
https://doi.org/10.1182/blood.V130.Suppl_1.4303.4303
Published: 2017
Journal Articles

Results of a Phase 2 Trial Evaluating Efficacy and Safety of Entospletinib (GS-9973) in Patients with Mantle Cell Lymphoma

Jeffrey P. Sharman, Kathryn S. Kolibaba, Andrei R. Shustov, Thomas A. Giever, Leonard M. Klein, Derek Nay, Thomas A. Rado, Alfred Saleh, Danjie Zhang, Wen Shi, Andres Forero, Sarit Assouline
Journal: Blood
Blood (2016) 128 (22): 2963.
https://doi.org/10.1182/blood.V128.22.2963.2963
Published: 2016
Journal Articles

Temporal Profiles of Lymphocyte Subsets and the Correlation with Infectious Events in Idelalisib-Treated Patients

Jeffrey P. Sharman, Gilles A. Salles, Wojciech Jurczak, Jeffrey Jones, Carolyn J. Owen, MD MDes(UK), FRCPC, Veerendra Munugalavadla, Lyndah K. Dreiling, Yuanyuan Xiao, Arati V. Rao, Ian W. Flinn, MD PhD, Susan M. O'Brien, MD
Journal: Blood
Blood (2016) 128 (22): 5583.
https://doi.org/10.1182/blood.V128.22.5583.5583
Published: 2016
Journal Articles

Evaluation of Immune Mechanisms to Understand Idelalislib-Associated Diarrhea-Colitis

Richard R. Furman, Michael Hallek, Jeffrey P. Sharman, Peter Hillmen, Andrew D. Zelenetz, Ian W. Flinn, MD PhD, Wojciech Jurczak, Veerendra Munugalavadla, Yuanyuan Xiao, Lianqing Zheng, Arati V. Rao, Lyndah K. Dreiling, Gilles A. Salles, Susan M. O'Brien, MD
Journal: Blood
Blood (2016) 128 (22): 5588.
https://doi.org/10.1182/blood.V128.22.5588.5588
Published: 2016
Journal Articles

A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials

Laurie H Sehn, MD, Michael Hallek, Wojciech Jurczak, Jennifer R. Brown, Paul M. Barr, John Catalano, Steven E. Coutre, MD, Richard R. Furman, Nicole Lamanna, Ysebaert Loïc, Andrew D. Zelenetz, Jeffrey P. Sharman, Sven DeVos, Adeboye Henry Adewoye, Yeonhee Kim, Ian W. Flinn, MD PhD, Gilles A. Salles
Journal: Blood
Blood (2016) 128 (22): 3705.
https://doi.org/10.1182/blood.V128.22.3705.3705
Published: 2016
Journal Articles

Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of the B-Cell Receptor Signaling Pathway

Jeffrey P. Sharman, Andrei R. Shustov, Mitchell R. Smith, Christopher T. Hagenstad, Kathryn S. Kolibaba, Esteban Abella-Dominicis, Danjie Zhang, Siddhartha Mitra, Christopher A. Yasenchak, Farrukh T. Awan
Journal: Blood
Blood (2016) 128 (22): 3225.
https://doi.org/10.1182/blood.V128.22.3225.3225
Published: 2016